Home > Riviste > Minerva Endocrinologica > Fascicoli precedenti > Minerva Endocrinologica 2017 June;42(2) > Minerva Endocrinologica 2017 June;42(2):122-31

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

MINERVA ENDOCRINOLOGICA

Rivista sulle Malattie del Sistema Endocrino


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,383


eTOC

 

REVIEW  ENDOCRINE AND METABOLIC DISORDERS INTERPLAYING WITH NON-ALCOHOLIC FATTY LIVER DISEASEFREEfree


Minerva Endocrinologica 2017 June;42(2):122-31

DOI: 10.23736/S0391-1977.16.02564-5

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Prevalence, etiology and management of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome

Evangelia MAKRI, Konstantinos TZIOMALOS

First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece


PDF  


Obesity and insulin resistance (IR) are frequently present in patients with polycystic ovary syndrome (PCOS). Both disorders also play an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Accordingly, NAFLD is frequently present in patients with PCOS. In the present review, we summarize the findings of the major studies that assessed the prevalence of NAFLD in patients with PCOS. The factors driving the increased frequency of NAFLD in patients with PCOS are also analyzed. Finally, we discuss the management options of NAFLD in patients with PCOS. In addition to IR, elevated androgen levels and inflammation also appear to play a role in the development and progression of NAFLD in patients with PCOS. Lifestyle changes should represent the cornerstone of management of NAFLD. On the other hand, pharmacotherapy appears to have limited efficacy and questionable safety. Moreover, there are very limited data with the various agents used for the management of NAFLD specifically in patients with PCOS. Accordingly, well-designed studies are clearly needed to evaluate the role of pharmacotherapy in the management of NAFLD in PCOS.


KEY WORDS: Polycystic ovary syndrome - Non-alcoholic fatty liver disease - Insulin resistance - Diet - Drug therapy

inizio pagina

Publication History

Issue published online: February 6, 2017
Article first published online: October 25, 2016

Per citare questo articolo

Makri E, Tziomalos K. Prevalence, etiology and management of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome. Minerva Endocrinol 2017;42:122-31. DOI: 10.23736/S0391-1977.16.02564-5

Corresponding author e-mail

ktziomalos@yahoo.com